SynthesisFrontiers in pharmacology2026
Screening traditional Chinese medicine monomers for premature ovarian insufficiency: from network meta-analysis to the effects of a promising candidate on oxidative stress biomarkers.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Therapeutic options for premature ovarian insufficiency (POI) are limited, and the comparative efficacy of traditional Chinese medicine (TCM) monomers remains unclear. This study aimed to systematically evaluate and rank the efficacy of various TCM monomers in animal models of POI and to explored the potential role of oxidative stress modulation by a promising candidate. Methods: Eight electronic databases (PubMed, Embase, the Cochrane Library, Web of Science, CNKI, VIP, Wanfang Database, and SinoMed) were searched from inception to 3 April 2026, for randomized controlled animal trials evaluating single TCM monomers in POI models. The SYRCLE tool and CINeMA were employed to assess the risk of bias and the certainty of evidence, respectively. A frequentist network meta-analysis was conducted to compare primary and secondary ovarian function outcomes, with relative efficacy ranked by the surface under the cumulative ranking curve (SUCRA) values. Pairwise meta-analyses were then performed to evaluate the effects of a candidate monomer on oxidative stress biomarkers. Three-dimensional scatter plots were used to visualize potential trends in primary outcomes regarding the relationships among dose, treatment duration, and therapeutic efficacy. Results: Thirty-two studies involving 676 animals and six TCM monomers were included. Compared with controls, all monomers significantly reduced serum follicle-stimulating hormone and increased estradiol levels. Furthermore, quercetin and icariin promoted follicular development and suppressed atresia., although the certainty of evidence was very low. Based on global mean SUCRA values, quercetin ranked first in the main analysis and emerged as a promising candidate overall. Pairwise analyses showed that quercetin increased serum superoxide dismutase and catalase while decreasing malondialdehyde levels. Exploratory three-dimensional visualization suggested a potential enhanced therapeutic trend for quercetin within the dosage range of 25-100 mg/kg over 10-30 days. Conclusion: Several TCM monomers improved ovarian function in POI models. Quercetin was considered a promising candidate, with its potential effect likely associated with the modulation of oxidative stress biomarkers. Given the substantial heterogeneity and very low evidence certainty, these findings should be interpreted with caution. Further rigorous, standardized preclinical dose-response studies and well-designed clinical trials are warranted to facilitate the clinical translation of these findings. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261359490, identifier CRD420261359490.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.